U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906731) titled 'A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors' on March 26.
Brief Summary: This is an open label, multi-center, multiple doses Phase I/II study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of SHR-9803 for injection in subjects with advanced solid tumors.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: SHR-9803
SHR-9803
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....